The National Heart, Lung, and Blood Institute (NHLBI) is the fourth largest institute in the US National Institutes of Health (NIH). Surprisingly, there is a conspicuous void of policy studies related to the research activities of NHLBI in comparison to NIH or the National Cancer Institute. This paper investigates the likelihood that a business funded through NHLBI’s Small Business Innovation Research (SBIR) program will commercialize from its Phase IIB translational support. Commercialization is one performance metric that quantifies a policy dimension of the success of the funded SBIR project. Based on an empirical analysis of sixty-one Phase IIB projects, we find that the most significant covariate with the likelihood of commercialization is the growth in human capital within the business since the Phase IIB award.

中文翻译：

---

将技术推向市场：国家心肺血液研究所 SBIR IIB 期项目

美国国家心肺血液研究所 (NHLBI) 是美国国立卫生研究院 (NIH) 的第四大研究所。令人惊讶的是，与 NIH 或国家癌症研究所相比，NHLBI 的研究活动相关的政策研究明显缺乏。本文调查了通过 NHLBI 小型企业创新研究 (SBIR) 计划资助的企业通过其 IIB 期转化支持实现商业化的可能性。商业化是一种绩效指标，用于量化受资助的 SBIR 项目成功的政策维度。基于对 61 个 IIB 期项目的实证分析，我们发现与商业化可能性最显着的协变量是自 IIB 期授予以来企业内部人力资本的增长。